Overview

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Status:
Completed
Trial end date:
2019-12-09
Target enrollment:
Participant gender:
Summary
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
Phase:
Phase 2
Details
Lead Sponsor:
Nationwide Children's Hospital
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Oxaliplatin
Paclitaxel